Sign inJoin waitlistJoin the waitlist

AD

Alexander Drilon

Chief, Early Drug Development Service · New York Presbyterian Hospital

Credentials: · · · ·

History

Early Drug Development Service Division · New York Presbyterian Hospital
Present
Early Drug Development & Thoracic Oncology Division · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2007–2009
Internal Medicine
Mount Sinai Morningside
2004–2007
UNIV OF THE PHILIPPINES, MANILA
2000–2004

Research

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · First of 38 authors · 2,193 citations
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
The Lancet Oncology · 2020 · 1,363 citations
NTRK fusion-positive cancers and TRK inhibitor therapy
Review · Nature Reviews Clinical Oncology · 2018 · Last of 3 authors · Corresponding · 1,171 citations

ML
Marc Ladanyi
68 papers
MK
Mark Kris
48 papers
MA
Maria Arcila
45 papers
Charles Rudin
38 papers
BL
Bob Li
36 papers
GR
Gregory Riely
35 papers
DH
David Hyman
33 papers
MO
Michael Offin
30 papers · 17 as a fellow
AS
Alison Schram
27 papers · 6 as a fellow
NR
Natasha Rekhtman
27 papers
SY
Soo-Ryum Yang
24 papers · 5 as a fellow
GH
Guilherme Harada
22 papers

Grants

Targets for Therapy for Carcinomas of the Lung
National Cancer Institute · P01
PI · $2.4M · Sloan-Kettering Inst Can Research
2007–2031
Investigational Cancer Therapeutics Training Program (ICTTP)
National Cancer Institute · T32
Contact PI · $2.4M · Sloan-Kettering Inst Can Research
1977–2029
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy
National Cancer Institute · R01
PI · $3.6M · Sloan-Kettering Inst Can Research
2022–2027
Predicting Sensitivity and Resistance in RET-Driven Cancers
National Cancer Institute · R01
Contact PI · $2M · Sloan-Kettering Inst Can Research
2021–2027

Clinical trials

Continued Access to RXDX-105
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2018–2020
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2012–2027
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Site PI · Recruiting · Phase 1, Phase 2
TRIANA Biomedicines, Inc.
2026–2034
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Site PI · Recruiting · Phase 3
Nuvation Bio Inc.
2025–2033